SK Biopharmaceuticals and ProEn Therapeutics: A New Chapter in Radiopharmaceuticals

SK Biopharmaceuticals, a global leader in the development of treatments for central nervous system (CNS) disorders and oncology, has recently inked a research collaboration agreement with ProEn Therapeutics. This strategic partnership aims to accelerate the expansion of oncology research and pipeline for global competitiveness in radiopharmaceuticals. The collaboration seeks to advance up to two preclinical candidates for the development of novel radiopharmaceutical drugs by 2027, leveraging ProEn Therapeutics' innovative ArtBody™ platform.

The ArtBody™ platform, a bivalent binder technology, incorporates small proteins to selectively target tumor cells. This dual-target binding technology enhances tumor selectivity, minimizing damage to healthy tissues. The platform's intrinsic advantages, such as high stability and structural robustness, make it ideal for industrial applications. By leveraging this platform, SK Biopharmaceuticals aims to develop more effective and safer radiopharmaceutical therapies, further expanding its oncology research and pipeline for global competitiveness.

Small proteins offer several advantages in radiopharmaceutical therapy. Firstly, they have superior tumor penetration compared to antibodies, allowing them to reach and target specific tumor antigens more effectively. This enhanced selectivity minimizes damage to healthy tissues, reducing potential side effects. Secondly, small proteins clear faster from the body, which can lead to reduced toxicity and improved patient safety. Lastly, they are more cost-efficient to manufacture, addressing key challenges in antibody-based drug development, such as high manufacturing costs and potential toxicity issues. These advantages make small proteins an attractive option for radiopharmaceutical therapy, driving an increasing focus from pharma and biotech companies worldwide.

The collaboration between SK Biopharmaceuticals and ProEn Therapeutics aligns with SK Biopharmaceuticals' strategy to become a global leading RPT player by 2027. This joint research builds on the momentum of SK Biopharmaceuticals' global strategic partnerships, including the in-licensing of a radiopharmaceutical compound and a supply agreement to secure actinium-225, an alpha-particle emitting radioisotope. By combining ProEn Therapeutics' ArtBody™ platform with SK Biopharmaceuticals' radiopharmaceutical therapy business, the two companies aim to develop more effective, safer treatments, further accelerating their expansion in oncology research and global competitiveness in radiopharmaceuticals.



In conclusion, the research collaboration agreement between SK Biopharmaceuticals and ProEn Therapeutics marks a significant step forward in the development of novel radiopharmaceutical drugs. By leveraging the ArtBody™ platform and the advantages of small proteins, the two companies aim to develop more effective and safer treatments for cancer patients. This strategic partnership aligns with SK Biopharmaceuticals' long-term vision of becoming a global leading RPT player and further expanding its oncology research and pipeline for global competitiveness in radiopharmaceuticals.